3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
11
Sarcoma
4
Gynecologic
4
Genitourinary
3
Gastrointestinal
3
Breast
3
Thoracic
2
Dermatologic
2
NET
1
Lymphoid
1
Endocrine
1
CNS
1
Conditions
Lymphoma
111
Precursor Cell Lymphoblastic Leukemia-Lymphoma
109
Lymphoma, Non-Hodgkin
105
Leukemia, Lymphocytic, Chronic, B-Cell
88
Lymphoma, Large B-Cell, Diffuse
84
Lymphoma, Follicular
68
Hodgkin Disease
54
Burkitt Lymphoma
52
Multiple Myeloma
51
Lymphoma, B-Cell
51
Recurrence
46
Lymphoma, Mantle-Cell
46
Leukemia, Myeloid, Acute
44
Leukemia
37
Neoplasms
35
Hematologic Neoplasms
32
Myelodysplastic Syndromes
29
Lymphoma, B-Cell, Marginal Zone
26
Waldenstrom Macroglobulinemia
22
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
19
Lymphoma, T-Cell
18
Lymphoma, T-Cell, Peripheral
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Leukemia, B-Cell
16
Lymphoma, Large-Cell, Anaplastic
15
Sarcoma
13
Leukemia, Biphenotypic, Acute
13
Mycosis Fungoides
11
Melanoma
10
Lymphoma, T-Cell, Cutaneous
10
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Lymphoid
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA